Hamm C W
Abteilung Kardiologie, Medizinische Klinik Universitätskrankenhaus Eppendorf, Hamburg.
Z Kardiol. 1998;87 Suppl 2:171-4. doi: 10.1007/s003920050557.
Treatment of symptomatic multivessel coronary disease with balloon angioplasty (PTCA) or bypass surgery as based on the results of 5 large, randomized trials is equivalent with respect to clinical outcome and risk. After PTCA, however, the rate of reinterventions is considerably higher. During long-term follow-up in the BARI trial, mortality was lower in diabetic patients undergoing surgery. Individual therapeutic decision making by the treating physician proved to be an important factor for the patients' prognosis. The role of new devices (stents) is currently under investigation in new large randomized trials.
根据5项大型随机试验结果，采用球囊血管成形术（PTCA）或搭桥手术治疗有症状的多支冠状动脉疾病，在临床结果和风险方面是等效的。然而，PTCA术后再次干预的发生率要高得多。在BARI试验的长期随访中，接受手术的糖尿病患者死亡率较低。事实证明，治疗医生的个体化治疗决策是影响患者预后的重要因素。新设备（支架）的作用目前正在新的大型随机试验中进行研究。
